Could COVID-19 Wake Up the Virus Behind Mono? What the Research Really Suggests
Could COVID-19 Wake Up the Virus Behind Mono? What the Research Really Suggests
From the early days of the pandemic, it became clear that COVID-19 was not always a short, self-contained illness. For some people, the infection was followed by weeks or months of fatigue, brain fog, poor exercise tolerance, and a lingering sense that the body had not quite returned to normal.
That persistence pushed researchers to ask a harder question: what if some of the ongoing symptoms were not caused by the coronavirus alone, but by the way it disrupted the immune system?
One virus has become central to that discussion: Epstein-Barr virus, or EBV. It is best known for causing infectious mononucleosis, often called mono, but what makes it especially important is that it does not fully leave the body after the initial infection. Like other herpesviruses, it can remain dormant for years and reactivate under the right conditions.
The evidence supplied here suggests COVID-19 may be linked to that kind of reactivation — or to immune disturbances that make EBV activity more likely. That is not the same as showing that COVID-19 directly causes classic mono in large numbers of people. But it does support a growing idea in post-viral medicine: SARS-CoV-2 may sometimes disrupt the balance between the immune system and viruses that were already quietly living in the body.
Why Epstein-Barr keeps coming up
EBV is extraordinarily common. Most people are infected at some point in life, often in childhood or adolescence. In some cases it causes mono, with symptoms such as fever, sore throat, swollen lymph nodes, and profound fatigue. In many others, the infection is mild or unnoticed.
What matters for this story is what happens afterwards.
Once the initial infection settles, EBV can remain latent inside the body. It is not gone. It is simply kept in check by the immune system. If immune surveillance weakens or becomes dysregulated, the virus can reactivate.
That does not always mean someone will develop full-blown mono again. Reactivation can be subtler than that. It may show up as detectable viral activity, changes in immune markers, or symptoms that overlap with post-viral syndromes.
This is why COVID-19 has drawn attention. Researchers do not need it to cause a brand-new EBV infection from scratch. The more plausible concern is that it may disturb the immune environment enough to let a latent virus become active again.
What the research actually shows
The most relevant study in the supplied evidence found that Epstein-Barr virus viremia at the time of COVID-19 diagnosis was one of several factors associated with later post-acute COVID-19 sequelae. In simple terms, people who showed signs of EBV activity while they had COVID-19 were more likely to go on to experience lingering symptoms afterwards.
That finding matters because it offers a biological link between SARS-CoV-2 infection and EBV activity. It does not prove that EBV is causing all long-term symptoms. It does not prove that COVID-19 is creating a wave of new mono cases. But it does suggest that the virus behind mono may be part of the broader post-COVID picture in at least some patients.
The second supplied source, a review on COVID-19 and carcinogenesis, is more indirect. It discusses co-infections with oncogenic viruses such as EBV as part of the longer-term consequences of immune disruption after COVID-19. That is not direct evidence about glandular fever or mono diagnoses, but it strengthens the broader idea that SARS-CoV-2 may alter the body’s relationship with latent viruses.
Taken together, the literature supports plausibility. It supports an association. What it does not yet provide is straightforward proof that COVID-19 directly causes infectious mononucleosis in a large epidemiologic sense.
Why this matters for long COVID
One reason the EBV hypothesis has attracted so much attention is that it could help explain part of the long COVID puzzle.
Many symptoms reported in post-acute COVID syndromes — especially severe fatigue, poor stamina, difficulty concentrating, and a lingering post-illness crash — overlap with the kinds of symptoms people associate with mono or other EBV-related illness. That does not mean the two are the same. Long COVID is likely a complex syndrome with multiple biological drivers, including inflammation, vascular changes, autonomic dysfunction, tissue injury, and perhaps persistent immune activation.
But EBV reactivation may be one piece of that puzzle.
That matters because it offers a more biologically grounded explanation for symptoms that have often seemed frustratingly hard to categorize. It shifts the conversation away from the idea that patients are simply recovering slowly in a vague or unexplained way. Instead, it suggests there may be measurable post-viral interactions occurring inside the immune system.
Why the headline still needs restraint
This is exactly where caution matters.
The supplied PubMed evidence does not directly study incident glandular fever after COVID-19 in a large cohort. It does not provide absolute risk figures. It does not show how often clinically diagnosed mono occurs after SARS-CoV-2 infection. And the most relevant paper is focused on post-acute COVID symptoms and EBV viremia, not on classic infectious mononucleosis as a primary outcome.
That means the stronger version of the headline — that COVID-19 increases the risk of glandular fever in a direct and clearly demonstrated way — goes further than the evidence in hand.
A more accurate reading is that COVID-19 may be linked to Epstein-Barr reactivation or EBV-related immune disturbances, and that this may help explain some downstream symptoms after infection.
That is a meaningful finding. It is just not the same as proving a surge in straightforward mono diagnoses.
What this could mean for patients
For people dealing with lingering symptoms after COVID-19, this research offers two important messages.
The first is validating: persistent fatigue, brain fog, and post-viral malaise may have real biological underpinnings even when routine tests do not immediately explain them. The interaction between SARS-CoV-2, immune dysregulation, and latent viruses offers one plausible mechanism.
The second is practical: not every case of prolonged symptoms after COVID-19 should be assumed to be EBV reactivation or mono. Fatigue and poor recovery can result from many overlapping issues, including autonomic dysfunction, cardiovascular effects, respiratory limitations, sleep disruption, mental health strain, endocrine changes, or other immune disturbances.
In other words, this is a clue — not a complete diagnosis.
Why this story is bigger than one virus
The broader importance of this research is that it changes how post-viral illness is understood.
For a long time, infections were often framed as isolated events: a virus enters, causes symptoms, and then the body clears it. COVID-19 has made that model look incomplete. In some people, the after-effects seem to involve a chain reaction — one infection that disturbs immune control over other biological processes, including latent infections that had previously stayed quiet.
If that framework holds up, it could reshape how clinicians think about recovery, long COVID, and post-viral syndromes more generally. It may also help explain why outcomes are so uneven. Two people can catch the same virus and end up on very different recovery paths, perhaps because one person’s immune system regains control quickly while another’s remains unsettled for much longer.
For Canada, where long COVID remains an ongoing public health concern, that distinction matters. It affects how patients are monitored, how symptoms are validated, and what kinds of biological markers researchers look for next.
The most honest takeaway
The evidence here is weak and indirect, but it points in a coherent direction. COVID-19 may help reactivate Epstein-Barr virus — or at least create the kind of immune disturbance in which EBV becomes more active.
That does not amount to proof that COVID-19 is causing classic mono in a simple, large-scale way. It does not tell us how common that risk is, and it does not settle whether EBV is a driver of symptoms, a marker of immune stress, or one part of a larger post-viral process.
What it does do is open an important window into how COVID-19 may continue to affect the body after the acute infection has passed.
This is not just a story about mono. It is a story about what happens when one virus disrupts the body enough to let old, hidden infections speak up again. And that may turn out to be one of the most important lessons of the post-COVID era.